Xenon Pharmaceuticals (XENE) Shares Outstanding (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Shares Outstanding data on file, last reported at $96.6 million in Q1 2026.

• Shares Outstanding for Q1 2026 came in at $96.6 million, up 26.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $96.6 million (up 26.16% YoY), and the FY2025 annual result was $80.0 million, up 4.7% from the prior year.
• Shares Outstanding rose to $96.6 million in Q1 2026 per XENE's latest filing, from $80.0 million in the prior quarter.
• Over five years, Shares Outstanding peaked at $96.6 million in Q1 2026 and troughed at $53.1 million in Q1 2022.
• A 5-year average of $71.7 million and a median of $75.5 million in 2024 frame the typical range for Shares Outstanding.
• The sharpest annual moves came in 2022 and 2024: Shares Outstanding surged 51.38% in 2022, then grew 1.39% in 2024.
• A 5-year view of Shares Outstanding shows it stood at $62.6 million in 2022, then increased by 20.42% to $75.4 million in 2023, then climbed by 1.39% to $76.4 million in 2024, then gained by 4.7% to $80.0 million in 2025, then climbed by 20.76% to $96.6 million in 2026.
• Business Quant data shows XENE's Shares Outstanding at $96.6 million in Q1 2026, $80.0 million in Q4 2025, and $77.1 million in Q3 2025.